Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy

European Journal of Heart Failure

Volumn 10, Issue 3, 2008, Pages 298-307

  Fantoni, Cecilia ^a,c,d   Regoli, François ^a   Ghanem, Ali ^a   Raffa, Santi ^a   Klersy, Catherine ^e   Sorgente, Antonio ^b   Faletra, Francesco ^b   Baravelli, Massimo ^c,f   Inglese, Luigi ^d   Salerno Uriarte, Jorge A ^c   Klein, Helmut U ^a   Moccetti, Tiziano ^b   Auricchio, Angelo ^a,b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b DIVISION OF CARDIOLOGY   (Switzerland)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f Division of Cardiology   (Italy)

Author keywords

Cardiac resynchronization therapy; Diabetes mellitus; Heart failure; Outcome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROHORMONE;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DEATH; DEFIBRILLATOR; DIABETES MELLITUS; DISEASE FREE SURVIVAL; EPICARDIUM; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMPLANTATION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AUTONOMIC NERVOUS SYSTEM; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; DIABETIC ANGIOPATHIES; FEMALE; HEART FAILURE; HUMANS; INSULIN RESISTANCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACEMAKER, ARTIFICIAL; TREATMENT OUTCOME;

EID: 40249091264     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.01.006     Document Type: Article

References (44)

1. Kannel W.B., and McGee D.I. Diabetes and cardiovascular disease: the Framingham study. JAMA 241 (1979) 2035-2038
2. Soläng L., Malmberg K., and Ryden L. Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J 20 (1999) 789-795
3. Nichols G.A., Hillier T.A., Erbey J.R., and Brown J.B. Congestive heart failure in type 2 diabetes: prevalence, incidence and risk factors. Diabetes Care 24 (2001) 1614-1619
4. Aronow W.S., and Ahn C. Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest 115 (1999) 867-868
5. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974) 29-34
6. Shindler D.M., Kostis J.B., Yusuf S., et al. Diabetes mellitus: a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 77 (1996) 1017-1020
7. Smooke S., Horwich T.B., and Fonarow G.C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149 (2005) 168-174
8. De Groote P., Lamblin N., Mouquet F., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25 (2004) 656-662
9. Tenenbaum A., Motro M., Fisman E.Z., et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 114 (2003) 271-275
10. Suskin N., McKelvie R.S., Burns R.J., et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21 (2000) 1368-1375
11. Auricchio A., Stellbrink C., Sack S., et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 39 (2002) 2026-2033
12. Abraham W.T., Fisher W.G., Smith A.L., et al. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. New Engl J Med 346 (2002) 1845-1853
13. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
14. Asbun J., and Villarreal F.J. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47 (2006) 693-700
15. Randle P.J., Garland P.B., Newsholme E.A., and Hales C.N. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
16. Schmidt A.M., Yan S.D., Wautier J.L., and Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84 (1999) 489-497
17. Vehkavaara S., Seppala-Lindroos A., Westerbacka J., Groop P.H., and Yki-Jarvinen H. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 22 (1999) 1055-1060
18. Julu P. Vagolytic effect of diabetes mellitus. Brain 116 (1993) 485-492
19. Kies P., Bax J.J., Molhoek S.G., et al. Comparison of effectiveness of cardiac resynchronization therapy in patients with versus without diabetes mellitus. Am J Cardiol 96 (2005) 108-111
20. Hoppe U.C., Freemantle N., Cleland J.G., Marijianowski M., and Erdmann E. Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. Diabetes Care. 30 (Mar 2007) 722-724
21. Cockroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
22. Fantoni C., Raffa S., Regoli F., et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol 46 (2005) 1875-1882
23. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Engl J Med 335 (1996) 1933-1940
24. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
25. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 2225-2237
26. Gasparini M., Auricchio A., Regoli F., et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 48 (2006) 734-743
27. Epstein A.E., Carlson M.D., Fogoros R.N., Higgins S.L., and Venditti Jr. F.J. Classification of death in antiarrhythmic trials. J Am Coll Cardiol 27 (1996) 433-442
28. Masoudi F.A., and Inzucchi S.E. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99 4A (2007) 113B-132B
29. The BEST Investigators. The Beta-Blocker Evaluation of Survival Trial (BEST). N Engl J Med 344 (2001) 1659-1667
30. Fonarow G.C., Corday E., and ADHERE Scientific Advisory Committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 9 (2004) 179-185
31. Domanski M., Krause-Steinrauf H., Deedwania P., et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42 (2003) 914-922
32. Nodari S., Metra M., Dei Cas A., and Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail 5 (2003) 803-809
33. Stewart K.J. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA 288 (2002) 1622-1631
34. McAuley K.A., Williams S.M., Mann J.I., et al. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care 25 (2002) 445-452
35. Castaneda C., Layne J.E., Munoz-Orians L., et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 25 (2002) 2335-2341
36. Adamson P.B., Smith A.L., Abraham W.T., et al. Continuous autonomic assessment in patients with symptomatic heart failure. Prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 110 (2004) 2389-2394
37. Singh J.P., Larson M.G., O'Donnell C.J., et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 86 (2000) 309-312
38. Kontopoulos A.G., Athyros V.G., Didangelos T.P., et al. Effect of chronic quinalapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 20 (1997) 355-361
39. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2 (1983) 755-763
40. Packer M., Bristow M.R., Cohn J.N., et al. The effect of cavedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
41. Ryden L., Armstrong P.W., Cleland J.G., et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 21 (2000) 1967-1978
42. Erdmann E., Lechat P., Verkenne P., and Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high risk patient groups with chronic heart failure. Eur J Heart Fail 3 (2001) 469-479
43. Auricchio A., Metra M., Gasparini M., et al. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol. 99 (2007) 232-238
44. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., and Gersch B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 421-428